FibroBiologics, Inc. (FBLG)
| Market Cap | 262.41M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -19.06M |
| Shares Out | 32.72M |
| EPS (ttm) | -0.68 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 82,364 |
| Open | 7.05 |
| Previous Close | 6.72 |
| Day's Range | 7.05 - 8.02 |
| 52-Week Range | 6.53 - 46.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 14, 2024 |
About FBLG
FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas. [Read more]
Financial Performance
Financial StatementsNews
FibroBiologics Granted Patent for Regeneration of Cartilage-Type Cells by the Australian Patent Office
HOUSTON, April 11, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the deve...
FibroBiologics Presents Data from Dermal Fibroblast Spheroid-based Treatment of Chronic Wounds in a Diabetes Mouse Model at Advanced Wound Care Summit USA
HOUSTON, April 04, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending for the development of ...
FibroBiologics Files Patent Application Covering Fibroblast-based Technology for the Potential Treatment of Lupus
HOUSTON, March 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the developmen...
FibroBiologics Announces Preliminary Proof of Concept for Fibroblast-based Diabetes Treatment
HOUSTON , March 19, 2024 /PRNewswire/ -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the develo...
FibroBiologics to Present at Advanced Wound Care Summit USA
HOUSTON , March 13, 2024 /PRNewswire/ -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the develo...
FibroBiologics Appoints Ruben A. Garcia as General Counsel
HOUSTON , March 6, 2024 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the developm...
FibroBiologics Files 2023 Form 10-K Annual Report
HOUSTON , Feb. 29, 2024 /PRNewswire/ -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics") a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the developme...
FibroBiologics to Present Preclinical and Clinical Data at the 2024 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum
HOUSTON , Feb. 20, 2024 /PRNewswire/ -- FibroBiologics (Nasdaq: FBLG) ("FibroBiologics") is a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the development ...
FibroBiologics Presents Preclinical Data at the 2024 Keystone Symposia for Systemic Autoimmune and Autoinflammatory Diseases
HOUSTON , Feb. 13, 2024 /PRNewswire/ -- FibroBiologics (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company focused on the development of therapeutics and potential cures for chro...
FibroBiologics Announces Three United States Patents for Fibroblast Technology
HOUSTON , Feb. 8, 2024 /PRNewswire/ -- FibroBiologics (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company focused on the development of therapeutics and potential cures for chron...
FibroBiologics Announces Three Japanese Patents on Fibroblast Technology
HOUSTON , Feb. 6, 2024 /PRNewswire/ -- FibroBiologics (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company focused on the development of therapeutics and potential cures for chron...
FibroBiologics Announces Direct Listing on NASDAQ Under the Stock Ticker FBLG
HOUSTON , Jan. 31, 2024 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company focused on the development of therapeutics and potential cures fo...
FibroBiologics IPO Registration Document (S-1)
FibroBiologics has filed to go public with an IPO on the NASDAQ.